NK细胞对骨髓瘤RPMI 8226细胞的体外杀伤活性

目的:探讨NK细胞对骨髓瘤RPMI 8226细胞的体外杀伤活性.方法:分离纯化NK细胞,LDH法检测不同效靶比时NK细胞对RPMI 8226细胞的杀伤活性,并以K562细胞为对照.同时用甲基纤维素克隆形成试验观察效靶比为20:1时细胞克隆形成率.结果:NK细胞对K562、RPMI 8226细胞的杀伤活性随着效靶比升高而增强,在同一效靶比,NK细胞对K562、RPM1 8226细胞的杀伤活性组间比较差异均有统计学意义.NK细胞对K562细胞克隆形成抑制率为(63.48±6.78)%,对RPMI 8226细胞克隆形成抑制率为(23.71±2.39)%,差异有显著统计学意义.结论:NK细胞可杀伤骨髓瘤RPMI 8226细胞,但为低度敏感.     

环氧合酶-2抑制剂尼美舒利对白血病HL-60细胞增殖的抑制作用

 目的　探讨选择性环氧合酶-2（COX-2）抑制剂尼美舒利对人类急性髓系白血病HL-60细胞的增殖抑制作用。方法　以不同浓度的尼美舒利体外处理HL-60细胞,采用CCK-8、流式细胞术、Western blotting、ELISA等方法,检测尼美舒利对HL-60细胞增殖的作用及对细胞凋亡、细胞周期、COX-2、前列腺素E2（PGE2）、Bax、bcl-2、c-myc的影响。结果　尼美舒利对HL-60细胞增殖的抑制呈剂量、时间依赖性,可诱导细胞凋亡,将细胞周期阻滞于G0～G1期。尼美舒利作用HL-60细胞48 h后,细胞COX-2表达下调,100、200、400 μmol／L尼美舒利处理组与对照组HL-60细胞总凋亡率分别为（24.97±6.36）%、（34.22±5.76）%、（44.59±6.69）%及（4.11±1.26）%,差异有统计学意义（P＜0.05）。HL-60细胞合成PGE2减少,同时bcl-2、c-myc蛋白表达明显减少,Bax蛋白表达明显上调。结论　尼美舒利可抑制HL-60细胞增殖,诱导细胞凋亡,其作用与抑制COX-2表达,减少PGE2合成,阻滞细胞周期和调节凋亡相关蛋白bcl-2、c-myc、Bax的表达等有关。     

冠心病患者心率变异性的临床分析

目的 探讨冠心病心绞痛及心肌梗死(MI)患者的自主神经活动特点.方法 对60例健康者,50例心绞痛,40例陈旧性心肌梗死(OMI),60例急性心肌梗死(AMI)患者的心率变异性进行了对比研究.方法心绞痛以及MI患者的心率变异性明显低于正常人,AMI患者低于心绞痛以及OMI患者.结论 冠心病患者的自主神经活动受损,AMI患者更加明显,其迷走神经张力降低,而交感神经紧张性相对增强,发生恶性室性心律失常的危险性增加.     

人参皂甙-2A体外抗血小板作用的实验研究

目的探讨中药三七提取物人参皂甙-2A体外抗血小板作用。方法取高血压患者及正常人静脉血标本,常规制备富含血小板血浆,分别用不同浓度的硝苯地平、SK&F96365、人参皂甙-2A孵育,以2μmol/L二磷酸腺苷为诱聚药,连续5次测定5min血小板的聚集率,以血小板最大聚集率[maximal platelet aggregation rate,PAG(M)]为观察指标。结果(1)高血压患者PAG(M)为0．89±0．06,与正常人PAG(M) 0．68±0．07比较,差异有显著性(P＜0．01)；(2)两种浓度(10、20μmol/L)的硝苯地平对正常人和高血压患者PAG(M)均无影响；(3)不同浓度(2．5、5、10、20μmol/L)的SK&F96365对高血压病组的PAG(M)均有抑制作用；(4)不同浓度(2．5、5,10、20μmol/L)的人参皂甙-2A对高血压病组的PAG(M)均有抑制作用(P＜0．05,P＜0．01)；3种浓度(5、10、20μmol/L)的人参皂甙-2A对正常组的PAG(M)均有抑制作用(P＜0．05)。结论高血压患者血小板聚集功能明显高于正常人,血小板呈高反应状态,硝苯地平不能抑制...     

浅谈提高血液内科临床实习教学效果的几点体会

从临床能力、创造性思维、医德医风培养等几个方面,总结教学方法,以期提高血液内科临床实习教学效果。     

调脂过程中血小板超微结构和P—选择素的变化及关系

目的：研究高胆固醇血症（HC）患治疗前后血小板超微结构和血小板颗粒膜糖蛋白P－选择素表达的动态变化以及二的关系。方法：选择HC患20例,男7例,女13例,平均年龄52例,口服普伐他汀10－20mg/d,疗程4－8周,治疗前后在透射电镜下观察血小板的超微结构并进行立体计量分析,同时测定血小板颗粒膜糖蛋白P－选择素表达的变化。结果：HC患服用普伐他汀4－8周后血清总胆固醇和低密度脂蛋白及血小板P－选择素表达水平明显下降,同时血小板形态结构的立体计量学参数得以改善。结论：治疗后HC患血小板颗粒膜糖蛋白P－选择素表达的下降与血小板形态结构的恢复有关;而普伐他汀对血小板的这种良性影响,可能是其降脂以外,参与并促进动脉粥样斑块消退的多种机制之一。     

家兔动脉粥样硬化与血小板源内皮型氧化氮合酶表达的相关性

Objective To explore the correlation of atheroselerosis progression and the expression of platelet derived endothelial nitric oxide synthase (eNOS) in rabbits. Methods A total of 24 male New Zealand white rabbits were used in this study. Six of the animals were fed with normal food (control group). Eighteen rabbits were fed with cholesterol-rich food (1 g/d) for 12 weeks to establish the atherosclerosis model. Among 18 models, 6 rabbits were executed immediately and their aorta and platelet samples were collected for further analysis (model group), 6 rabbits were orally administered with pravastatin (10 rag/d) for additional 12 weeks (treated group), and the remaining 6 rabbits were left untreated until the end of the study (untreated group). The control, treated and untreated animals were then killed, and the aorta and platelet samples were collected for eNOS expression analysis (RT-PCR). Results The aorta samples in model and untreated group exhibited rough intima and a lot of longitudinal fatty streaks, which indicated that atherosclerosis models were established successfully. While in treated group, the degree of atherosclerosis was decreased. The average percent of thickness of fatty streaks or atheroselerotic plaques relative to the whole thickness of vessel walls was 0. 04±0. 02, 0. 82±0. 16, 0. 33±0. 18,0. 77±0. 14 in control, model, treated and untreated group, respectively. The thickness of fatty streaks or atherosclerotic plaques was significantly increased in the model and untreated groups and decreased in treated group compared with the control group (both P<0. 05). The expressions of platelet derived eNOS/mRNA were 1. 02± 0. 28, 0. 41± 0. 27, 1.00 ± 0. 77, 0. 40±0. 29 in control, model, treated and untreated group, respectively. The expression of eNOS/mRNA was markedly decreased in model group and untreated group compared with the control group, but was increased in treated group compared with untreated and model groups (F=3. 544, P = 0. 024). Conclusions There is a negative correlation between eNOS expression and atherosclerosis development, which suggests that the reversal effect of pravastatin on atheroselerosis progression and plaque formation may relate to the expression of platelet derived eNOS.     

持续静脉输注替罗非班对动脉硬化兔血浆炎症因子的影响

目的探讨血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班在体内持续应用对动脉硬化兔血浆炎症因子的影响,为动脉硬化时合理应用血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂提供理论依据。方法高脂饲料喂养新西兰大白兔12周形成动脉硬化模型后,分为4组,每组8只,分别恒速静脉滴注生理盐水、3.125、12.5 mg/L和50mg/L的替罗非班注射液,于注射0、12、24 h和48 h时,采用比浊法检测血小板最大聚集率和酶联免疫吸附法检测血浆P选择素、白细胞介素6、白细胞介素1β、肿瘤坏死因子α等炎症因子的水平,比较相关指标的变化。结果实验12、24 h和48 h时,随着替罗非班用药剂量增加,血小板最大聚集率逐渐减低(PANOVA<0.05),P选择素、白细胞介素1β、白细胞介素6、肿瘤坏死因子α逐渐减低(PANOVA<0.05)。对照组和3.125 mg/L替罗非班组12、24 h和48 h的血小板最大聚集率和0 h比较无改变(P>0.05);≥12.5 mg/L替罗非班用药后的血小板最大聚集率较用药0 h明显减低(P<0.05),P选择素、白细胞介素1β、白细胞介素6、肿瘤坏死因子α较0 h明显减低(P<0.05)。结论小剂量替罗非...     

高胆固醇血症治疗前后血小板立体计量学参数的变化

为研究高胆固醇血症对血小板超微结构及97立体计量学参数的影响及调脂药普伐他汀干预后的变化，选择高胆固醇血症患者20例，口服普伐他汀10－20mg/d，疗程4－8周，治疗前后在透射电镜下观察血小板的超微结构并进行立体计量分析。结果发现，治疗后高胆固醇血症患者血清总胆固醇和低密度脂蛋白水平及血小板聚集功能均明显下降，同时血小板形态结构的立体计量学参数得以改善。结果提示，高胆固醇血症患者血小板功能及立体计量学参数的可逆性变化可能与普伐他汀促进动脉粥样斑块消退的机制有关。